Ensysce Biosciences And OncoZenge Announce Letter Of Intent For The Co-Development Of BupiZenge In The U.S.
Portfolio Pulse from Benzinga Newsdesk
Ensysce Biosciences, Inc. (ENSC) and OncoZenge AB have signed a letter of intent for the co-development of BupiZenge™ in the U.S. BupiZenge™ is a non-opioid treatment for oral mucositis pain, a condition caused by cancer treatments. The collaboration aims to accelerate the commercialization of BupiZenge™ in the U.S. market, leveraging both companies' expertise. OncoZenge has completed Phase 2 trials in the EU, with plans for Phase 3. The partnership is expected to enhance patient care in analgesia and oncology by providing a new treatment option.
November 28, 2023 | 1:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ensysce Biosciences has entered into a strategic collaboration with OncoZenge to co-develop and commercialize BupiZenge™ in the U.S., aiming to address the unmet needs in pain management and oncology.
The partnership with OncoZenge to co-develop BupiZenge™ is likely to be viewed positively by investors as it represents progress towards expanding Ensysce's portfolio and entering a new market. The successful Phase 2 results in the EU and the move towards Phase 3 trials indicate a promising outlook for the drug's efficacy and safety, which could lead to increased investor confidence and a potential rise in stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 90